Zepbound in Adolescents Ages 12 to 17: Developmental Impact, Safety, and Clinical Guidance

What Is Zepbound and Why Are Clinicians Considering It for Teens?

Tirzepatide (Zepbound) is a once-weekly subcutaneous injection that activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. In adults, the SURMOUNT-1 trial (N=2,539) demonstrated 20.9% mean body weight reduction at 72 weeks on the 15 mg dose versus 3.1% for placebo [1]. That magnitude of weight loss has generated significant interest in applying tirzepatide to adolescent obesity.

Adolescent obesity is not a minor concern. The CDC's 2021 to 2023 National Health and Nutrition Examination Survey data place the prevalence of obesity among U.S. Teens ages 12 to 19 at 20.3% [2]. Severe obesity, defined as a BMI at or above the 120th percentile of the age-sex-specific growth chart, affects roughly 6.1% of adolescents and is associated with early-onset type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, and significant psychosocial burden [3].

The Gap Between Adult Efficacy and Adolescent Approval

Despite compelling adult data, the FDA has not approved Zepbound for patients younger than 18. Semaglutide 2.4 mg (Wegovy) received FDA approval for adolescents aged 12 and older in December 2022, based on the STEP TEENS trial (N=201), which showed 16.1% mean body weight reduction at 68 weeks versus 0.6% for placebo [4]. Tirzepatide is currently under Phase 3 investigation in the SURMOUNT-TEEN trial (NCT05673603), which is enrolling adolescents ages 12 to 17 with obesity; top-line data are anticipated in 2025 to 2026.

Why Adolescent Physiology Requires Its Own Data Set

Adult pharmacokinetic and pharmacodynamic data cannot be extrapolated directly to a 13-year-old mid-puberty. Body composition, renal clearance, hepatic enzyme activity, and hormonal milieu all differ substantially. The American Academy of Pediatrics (AAP) 2023 Clinical Practice Guideline on obesity states that "evidence-based obesity treatment for children and adolescents should be tailored to the child's age, developmental stage, and family context" [5]. Extrapolating adult dosing without age-stratified safety data carries real risk, particularly given the developmental processes described in the sections below.

Effects on Linear Growth and Height Velocity

Linear growth remains active through adolescence. Most teens do not reach skeletal maturity until age 17 to 18 in females and 19 to 21 in males. Any agent that significantly alters nutritional intake or hormonal signaling during this window could, in theory, affect final adult height.

GLP-1 Receptors and the Growth Axis

GLP-1 receptors are expressed in the hypothalamus, pituitary, and bone. Preclinical rodent studies have shown that chronic GLP-1 receptor agonism can modulate insulin-like growth factor 1 (IGF-1) signaling, a primary mediator of longitudinal bone growth [6]. Whether this translates into clinically meaningful height differences in humans over the 1 to 3 year treatment windows studied so far is unknown.

In the STEP TEENS trial of semaglutide, mean height velocity was not reported as a primary or secondary outcome, and no statistically significant difference in height was noted over 68 weeks [4]. That is reassuring but not definitive. Sixty-eight weeks may be too short a window to detect a 1 to 2 cm difference in final adult stature.

Monitoring Height in Clinical Practice

The Endocrine Society recommends plotting height on validated growth charts at every visit for any adolescent receiving pharmacotherapy for obesity [7]. A crossing of more than one height percentile channel downward over 6 months should prompt evaluation for growth hormone deficiency or insufficient caloric intake. Clinicians using tirzepatide off-label in adolescents must document baseline and serial height measurements at minimum every 3 months.

Bone Density and Peak Bone Mass Accrual

Peak bone mass is the single most important predictor of fracture risk later in life, and roughly 40% of lifetime skeletal mass is deposited during adolescence, particularly between ages 11 and 17 [8]. This makes bone a high-priority developmental concern with any therapy that reduces caloric intake or alters hormonal signaling during this window.

Caloric Restriction and Bone Accrual

GLP-1/GIP dual agonists reduce appetite and caloric intake substantially. In adults on tirzepatide 15 mg in SURMOUNT-1, estimated mean daily energy intake fell by approximately 550 kcal/day based on validated dietary recall [1]. An equivalent reduction in a 14-year-old who is still building bone could compromise calcium and vitamin D intake. Inadequate calcium during adolescence is associated with reduced bone mineral density (BMD) and elevated adult fracture risk [8].

Direct GIP Receptor Effects on Bone

The GIP receptor is highly expressed in osteoblasts and osteoclasts. GIP signaling normally exerts an anabolic effect on bone by stimulating osteoblast activity and inhibiting bone resorption [9]. Dual agonism of GIP receptors could theoretically support bone accrual, but dose-dependent and age-specific effects have not been characterized in human adolescents. This remains one of the most important unanswered questions in the field.

A practical clinical framework for monitoring bone health during off-label adolescent tirzepatide use would include: baseline DXA scan if BMI Z-score is above 2.0 (given that obesity itself can mask low bone density on standard screening), daily calcium intake targets of 1,300 mg per day per the Institute of Medicine, vitamin D 25(OH) levels checked at baseline and at 6 months, and a repeat DXA at 12 months if appetite suppression is significant [8].

Pubertal Timing and Reproductive Axis

Obesity in adolescence is already associated with altered pubertal timing. Girls with obesity more frequently experience early puberty, while boys with obesity may show delayed testicular development due to elevated aromatization of androgens to estrogens in adipose tissue [10]. Weight loss can normalize these hormonal disruptions, and this may be a genuine benefit of tirzepatide in teens.

GLP-1 and the Hypothalamic-Pituitary-Gonadal Axis

GLP-1 receptors are present in the hypothalamus, including in kisspeptin neurons that regulate gonadotropin-releasing hormone (GnRH) pulse frequency [11]. Kisspeptin is a master regulator of puberty onset. Preclinical data show that GLP-1 receptor activation can suppress kisspeptin firing under conditions of negative energy balance. Whether therapeutic tirzepatide doses produce sufficient hypothalamic GLP-1 receptor activation to alter GnRH pulsatility in teens has not been tested in clinical trials.

Clinicians prescribing tirzepatide off-label should obtain Tanner staging at baseline and every 6 months, with referral to a pediatric endocrinologist if pubertal progression appears to stall.

Menstrual Cycle Considerations

Adolescent females who achieve significant weight loss may experience changes in menstrual cycle regularity. This is generally positive in teens with polycystic ovary syndrome (PCOS), where weight loss improves menstrual regularity and reduces hyperandrogenism [12]. However, teens without PCOS who lose weight rapidly could develop functional hypothalamic amenorrhea. Monthly menstrual calendars and LH/FSH measurement at 6 months are reasonable monitoring steps.

Nutritional Status and Micronutrient Risk

Adolescents have the highest micronutrient requirements per kilogram of body weight of any age group outside infancy. Tirzepatide's appetite-suppressing mechanism reduces total food volume consumed, raising concern about inadequate intake of iron, calcium, vitamin D, zinc, folate, and vitamin B12.

Iron and Adolescent Development

Iron-deficiency anemia affects approximately 9% of U.S. Adolescent females already [13]. Adding a potent appetite suppressant could worsen dietary iron intake. Clinicians should check a complete blood count and serum ferritin at baseline and at 6-month intervals. Adolescent females on tirzepatide who menstruate should be strongly encouraged to consume iron-rich foods or take a low-dose iron supplement.

Protein Intake and Lean Mass Preservation

In the SURMOUNT-1 trial, approximately 17% of total weight lost in adult participants was lean mass [1]. Lean mass loss during adolescence is more concerning than in adults because adolescence is a period of active muscle accretion, particularly in males. Daily protein targets of 1.2 to 1.6 g/kg of ideal body weight are reasonable, supported by evidence from resistance-training studies in adolescents [14].

Practical Dietary Monitoring

Registered dietitian involvement is not optional for adolescents on any pharmacotherapy for obesity. The AAP 2023 guideline explicitly recommends that intensive lifestyle intervention, including dietary counseling, be a concurrent component of pharmacotherapy, not a prerequisite that is abandoned once a drug is prescribed [5].

Mental Health and Neurodevelopmental Considerations

Adolescence is a sensitive period for neurodevelopment. The prefrontal cortex continues maturing until approximately age 25, and reward circuitry is particularly plastic during the teen years [15]. Modifying appetite and food-reward signaling with a dual GIP/GLP-1 agonist during this window raises legitimate questions.

Mood, Anxiety, and the GLP-1 System

GLP-1 receptors are distributed throughout limbic and cortical brain regions. Preclinical data suggest GLP-1 receptor agonism can reduce anxiety-like behavior and improve hedonic food intake patterns [11]. In adult trials, semaglutide and tirzepatide have not shown statistically significant increases in depression or suicidality versus placebo. The FDA added a warning about suicidal ideation to liraglutide (Saxenda) labeling based on post-marketing reports, but a 2023 observational study in JAMA Internal Medicine (N=240,618) found that GLP-1 receptor agonists were not associated with increased suicidal events compared to other anti-obesity medications [16].

Adolescent-specific data are absent. The FDA requires pediatric safety reporting for mental health outcomes in any new pediatric indication filing, which is another reason waiting for SURMOUNT-TEEN data before widespread off-label use is prudent.

Body Image, Disordered Eating, and Medication Framing

Teen patients and their families may interpret significant weight loss as validation that thinness is the goal, rather than metabolic health. Clinicians should screen for disordered eating at baseline using the SCOFF questionnaire or the EDE-Q adapted for teens. Binge eating disorder (BED) and bulimia nervosa are more common in adolescents with obesity than in normal-weight peers, and pharmacotherapy for weight loss in the presence of untreated BED may worsen the psychological relationship with food [17].

Current FDA Status and Regulatory Context

Zepbound (tirzepatide) received FDA approval for chronic weight management in adults with obesity (BMI of 30 or above) or adults with BMI of 27 or above and at least one weight-related comorbidity in November 2023 [18]. The approval does not extend to pediatric patients.

The FDA's Pediatric Research Equity Act (PREA) requires sponsors to conduct pediatric studies for new indications. Eli Lilly is conducting SURMOUNT-TEEN (NCT05673603), a Phase 3 randomized, double-blind, placebo-controlled trial in adolescents ages 12 to 17 with obesity. The trial's primary endpoint is percentage change in body weight at 52 weeks. Secondary endpoints include Tanner stage progression, bone density, and height velocity, which are precisely the developmental parameters discussed above.

Off-label prescribing of tirzepatide to adolescents is not categorically prohibited by law in the United States, but it carries significant ethical, medicolegal, and clinical risk. The AAP guideline and the Obesity Medicine Association both recommend that pharmacotherapy in adolescents be provided by or in consultation with a specialist experienced in pediatric obesity management [5].

Comparing Tirzepatide to Approved Adolescent Options

Semaglutide 2.4 mg (Wegovy) is the only GLP-1 class agent currently FDA-approved for adolescents aged 12 and older. The STEP TEENS trial (N=201, ages 12 to 17) showed 16.1% mean weight reduction at 68 weeks with semaglutide versus 0.6% with placebo (P<0.001) [4]. Orlistat has FDA approval for ages 12 and older but achieves only 2 to 4% additional weight loss over lifestyle intervention and carries significant gastrointestinal tolerability issues.

Phentermine is approved for short-term use in patients 16 and older, though the evidence base in adolescents is limited. Topiramate/phentermine (Qsymia) carries FDA approval for adults but not for adolescents, and topiramate's cognitive side effects are particularly concerning in developing brains [17].

If tirzepatide's Phase 3 adolescent data replicate even 70% of the adult effect size, it would likely show approximately 14 to 15% weight reduction, which could exceed semaglutide's approved adolescent data. That would represent a meaningful clinical advance. Waiting for those data is the medically defensible position.

Practical Guidance for Clinicians Considering Off-Label Use

Some families and clinicians will not wait for a formal pediatric approval, particularly when a teen has severe obesity with life-limiting comorbidities. The following guidance applies to those situations only, with the understanding that this represents off-label use requiring careful documentation.

Before Starting

Obtain written informed consent and assent from both the parent or guardian and the adolescent. Document the specific comorbidities driving the decision. Obtain baseline labs including comprehensive metabolic panel, CBC with differential, lipid panel, HbA1c, fasting insulin, TSH, 25-OH vitamin D, ferritin, and LH/FSH. Record weight, height, BMI Z-score, and Tanner stage. Perform SCOFF screen for disordered eating.

Dosing Approach

Adult Zepbound dosing starts at 2.5 mg weekly for 4 weeks before titrating. No pediatric-specific dosing guidance exists. Given the lower average body weight and higher metabolic rate per kilogram in adolescents, some specialists argue for a more conservative titration schedule with longer intervals between dose increases. Nausea is the most common adverse event in adults, reported by 31.0% of the 15 mg group in SURMOUNT-1, and adolescents may be no less susceptible [1].

Ongoing Monitoring

Height and weight every 3 months. Tanner stage every 6 months. Menstrual calendar for females. Bone density DXA at baseline and 12 months. CBC and ferritin at 6-month intervals. Mood and disordered eating re-screening at every visit. Registered dietitian contact at minimum quarterly.

FAQ